HOME CARE EARLY DISCHARGE.



Similar documents
Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease

A Framework of Competences for the Level 3 Training Special Study Module in Paediatric Oncology

DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT

Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points

Blood & Marrow Transplant Glossary. Pediatric Blood and Marrow Transplant Program Patient Guide

Blood-Forming Stem Cell Transplants

SEARCHING FOR A BONE MARROW DONOR

Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation. April Reference: NHSCB/B04/P/a

Reference: NHS England B04/P/a

Pros and Cons of Stem Cell Sources and their availability in Africa. Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa

Other treatments for chronic myeloid leukaemia

Outcome of Unrelated HSCT in Patients Lacking HLA Matched Related Donors: Iranian Stem Cell Donor Program (ISCDP)

INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR

Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood

PERIPHERAL STEM CELL TRANSPLANT INTRODUCTION

Corporate Medical Policy

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each

Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine

Donating stem cells. What s involved?

TRANSPLANT BASICS Understanding transplant and how it works

Multiple Myeloma. This reference summary will help you understand multiple myeloma and its treatment options.

Graft Versus Host Disease:

STEM CELL TRANSPLANTS

Infosheet. Allogeneic stem cell transplantation in myeloma. What is the principle behind stem cell transplantation?

Cancer services children s CSCF v3.2

What is a Stem Cell Transplantation?

Acute Myeloid Leukemia

OUR JOURNEY THROUGH THE YEARS

Cord Blood Stem Cell Transplantation

Cord Cor Blood Banking Scott N. Furlan, MD Ellen S. Plummer, Plummer MD

February 1, Information Resource Center Publications Catalog

Stem Cell Banking. Umbilical Cord. The Leading Cell Bank Protect your family s future

Haematopoietic stem cell transplantation in Hong Kong

Severe Combined Immune Deficiency (SCID)

Stem Cell Transplantation In Patients with Fanconi Anemia

Name of Child: Date: About Blood Cells

Stem Cell Transplantation

Asymptomatic or smoldering myeloma with no symptoms and slow growing cancer cells

UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE

The future of unrelated Stem Cell Transplant in the UK: DOH Working Party Findings. Prof. Tony Pagliuca

Bone Marrow or Blood Stem Cell Transplants in Children With Severe Forms of Autoimmune Disorders or Certain Types of Cancer

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014

Bone Marrow/Stem Cell Transplant

What you need to know about. Multiple Myeloma. Based on a brochure from National Institutes of Health National Cancer Institute STDAVIDS.

UMBILICAL CORD BLOOD, STEM CELL BANKING

CANCER TREATMENT: Chemotherapy

Mayo Clinic College of Medicine Pharmacy Services. Rotation Summary

MEDICAL COVERAGE POLICY

Cancer in Children. What is cancer?

Stem Cell Transplant (Peripheral Blood, Bone Marrow, and Cord Blood Transplants)

Background: 1) Does your center have effective ways of collecting data from multiple sources to submit to multiple organizations?

Bone Marrow Transplant Services in New Zealand for Adults

STEM CELLS : A THERAPEUTIC REVOLUTION JACQUES KADOCH ROBERT HEMMINGS MARINELA MANDRA

CPT Codes for Bone Marrow Transplant January 2015 James L. Gajewski, MD

Public Cord Blood Tissue Bank Committee on Health Care Services and Representative Peaden

Helping you find the one match.. Guide for Unrelated Stem Cell Transplant Patients OneMatch Stem Cell and Marrow Network BLOOD.

Answering your questions on Chronic Myeloid Leukaemia (CML)

Not All Stem Cells are the Same

VAD Chemotherapy Regimen for Multiple Myeloma Information for Patients

ACUTE MYELOID LEUKEMIA (AML),

Bone Marrow or Blood Stem Cell Transplants in Children With Certain Rare Inherited Metabolic Diseases *

Acute myeloid leukaemia (AML) in children

Graft-versus-host disease (GvHD)

Kathie Viers-City of Hope Eric Presson- Baylor Health Care Systems Jennifer Christian-Markay Cancer Center

Specific Standards of Accreditation for Residency Programs in Pediatric Hematology/Oncology

The Infinite Potential of Stem Cell Japan s Cord Blood Bank and Transplant

SAVE A LIFE... BY GIVING LIFE!

Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris

PATIENT INFORMATION. Patient Name/Nombre

Many people with non-hodgkin lymphoma have found an educational support group helpful. Support

Treatment of low-grade non-hodgkin lymphoma

New Zealand Bone Marrow Donor Registry

Care of the Pediatric Oncology Patient. Lauren Ranallo, MSN, RN, AOCNS, CPHON Advanced Practice Nurse Hematology/Oncology/Transplant

HAEMOPHILIA & UMBILICAL CORD BLOOD TRANSPLANT

A guide for children who are having a stem cell transplant (SCT)

Hematopoietic Stem Cells, Stem Cell Processing, and Transplantation

BLOOD & MARROW TRANSPLANT IN CHILDREN

Stem Cell Transplantation and the Canadian First Nations Community. Becky Luk (PTLS) Tanya Petraszko, MD

GOING HOME AFTER YOUR TAVR PROCEDURE

Acute myeloid leukemia (AML)

OVERVIEW OF CURRENT STATUS OF STEM CELL TRANSPLANTATION IN VIETNAM

A fact sheet UNRELATED BONE MARROW AND CORD BLOOD STEM CELL TRANSPLANTS

Corporate Medical Policy

Transcription:

HOME CARE EARLY DISCHARGE. Eugenia Trigoso (PNG) Lucia Lopez (DM) Jose Mª Fernanadez (MDr.) 1 The European Group for Blood and Marrow Transplantation

Home care. Early discharge Introduction Major HSCT complications Discharge criteria Home care. Our experience Nurses role. 2

HSCT Paediatric Bone Marrow Transplantation has evolved over the past decade and is now an accepted and successful intensive therapy for a wide range of disorders in children. 3

Historical markers 1 1968 1975: the beginning of the Modern Era of human marrow transplantation. - Improved antibiotics. 1976 1986: widening application of allogeneic marrow grafting for human patients. - Increasing knowledge of HLA. 4

Historical markers 2 1986-present: haematopoietic cell transplantation as standard therapy. - Cyclophosphamide and busulfan. - Peripheral blood or cord blood. - Donors registries. 4

Major HSCT complications, first month Conditioning Infusion day Mucositis Bacteraemia Veno-occlusive diseasse Herpes Simplex Virus, Herpes 6 Disseminated fungal infections Acute GVHD Vomiting, diarrhea, fever, pain Days-7 0 7 14 21 30. 5

Major HSCT complications, first year Herpes Simplex Virus, Herpes 6 Disseminated fungal infections Aspergillus Veno-occlusive disease (VOD) Acute GVHD Chronic GVHD Vomiting, diarrhea, fever, pain Days 60 90 120 150 180.. 6

Discharge from Unit Engrafted (the ANC exceeded 0.5 x10 9 /l) Afebrile No significant infections or treatment related complications Without signs of bleeding (platelet count more than 10x10 9 /l) Able to take PO meds No pain or well controlled 7

Paediatric Oncologic Unit. is a reference centre for Comunidad Valenciana. We carry out an average of 25 transplants per year (autologus and allogenic including cord blood transplant). The most common underlying disease are ALL, AML and high risk Neuroblastoma. 8

Autologous: Types of transplants peripheral blood stem cell autologous bone marrow transplant Allogeneics: related unrelated cord blood transplant 9

Types of transplants Autologus Males (%) Females(%) 73 46 (63.01%) 27 (36.99%) Allogeneic 45 32 (71.11%) 13 (28.89%) 10

Overall activity last 6 years Autologus Allogeneics Total 2005 7 3 10 2006 11 7 18 2007 18 9 27 2008 12 8 20 2009 12 11 23 2010 13 7 20 13

January 2005-December 2010 Children: 110 Males : 70 Females: 40 Nº of transplants : 118 7 males twice, 1 of them 3 2 females twice. 14

Patients age ranged Patients' age at the time of BMT are ranged between: 6 months (0.60) and 20 years (20.01) median 7.01 years 15

Underlying diagnosis of the transplanted patients Osteosarcoma 1 Tumor de celulas Germinales 1 Hodgkin's lymphoma 3 Ependimoblastoma 1 Leiomiosarcoma 1 Linfoma 2 Acute lymphoblastic leukaemia 39 Acute myeloid leukaemia 29 Acute myeloid leukaemia + Fanconi A. 2 Ewing s Sarcoma 9 Neuroblastoma 18 Meduloblastoma 4 Myelodysplasia sindrome 1 Central nervous system tumours 1 Tumor rabdoide 2 Rabdomiosarcoma 1 16

the team one paediatric oncologist two paediatric nurses in morning shifts one clinical assistant support team 3 more paediatricians 2 more nurses 17

The team!!!

ADINO ADINO Atención Domiciliaria Teléfono: Integral a Niños Oncológicos 940331313 Abonado:37048 Mensaje: Nombre del niño y Teléfono de contacto Si no te llamamos en 10 ó 15 min. Repite tu mensaje Hospital Infantil La Fe Valencia 11

Como ya han sido informados durante Durante el tiempo en que su hijo esté La hospitalización de su hijo, la Unidad ingresado en ADINO, pueden contactar de Oncología Pediátrica del Hospital con la enfermera de guardia a través La Fe, dispone de un equipo para la del servicio busca personas hospitalización de los pacientes en Telf: 940331313 sus domicilios. Nº de abonado: 37048 Deben dejar como mensaje el nombre del niño y un nº de tlf. ADINO está formado por un médico, dos enfermeras y una auxiliar de clínica. Una de las enfermeras y el La enfermera se pondrá en contacto con médico responsable estarán ustedes tan pronto reciba el mensaje. localizables 24h al día, 7 días a la Si no les llamamos en 10 ó 15 min, repitan semana. su mensaje. Una vez su hijo ha sido dado de alta en ADINO, para resolver cualquier duda, deben llamar al teléfono de la Consulta Externa (963862789) horario días laborables de 8h. a 15h. 12

the scheduled The scheduled working time is: 24 hours a day 365 days a year, there are always a physician and a nurse on call. 18

the geographic area: Comunidad valenciana 19 23.255 km² and 5.094.675 inhabitants

Duration of the assistance Median duration of the assistance per child was 9.62 days Ranged between 2-84 days. Total of 1135 days. 20

Telephone calls Median of tlph. calls/patient : 9.12 Ranged between: 2 and 97. Total of 1076.0 21

blood tests Main procedures 1 i.v. therapy (antibiotics) total parenteral nutrition (TPN) transfusions central venous catheter (CVC) care and teaching symptom control pain control 22

Main procedures 2 provide all necessary medications and give every instruction they need coordinate care with the rest of health care team. (RX; labs. Day hospital) psychological support and. Going back home advices: 23

24 going back home advice

Preparing House Major cleaning some days prior to discharge Avoid home renovations prior to child's discharge 25

Cleaning house 1 Dust and vacuum Disinfect hard surfaces Clean bathroom that child uses daily and clean bathtub after each use Change filters often 26

Cleaning house 2 Disinfect kitchen well after each use, clean out fridge often Take out trash daily Avoid burning fireplace and stoves Patient's bedroom 27

Continue BMT daily routines Mouth care Mask Medications Low bacteria diet Avoid crowds Wash hands Light exercise 28

Skin care Shower daily Avoid bubble bath Moisture skin often Reduce sun exposure Sunscreen, sunglasses, hat, cover arms and legs 29

Avoid Swimming Hot tubs Sand boxes Construction sites Contact sports no birds, reptiles, chickens, ducks. 30

Conclusion Home care for transplanted patients programme give confidence to families makes easier transit to normal life permits to shorten the stay in the hospital The most common cause of discharge was the achievement of the goals. 31

Conclusion : nurses role-1 to support home care, allowing children to return home early following BMT to facilitate early discharge for the child and family to provide assessment and monitoring of the child after discharge 32

Conclusion : nurses role 2 to ensure appropriate education and information is given and reinforced to enable parents to feel confident and competent when caring for their child to make effective links within the day care hospital, primary care team, health care team and between hospital and community 33

Conclusion : nurses role 3 Major problems still need to be solved : >relapse after transplant >graft rejection >more effective and less toxic conditioning regimen >improve control of GvHD 34

Conclusion : nurses role 4 Nurses are vital in orchestrating the complicated care these therapies mandate, as well as providing emotional support to patients and their families. 34

Conclusion : nurses role 5 Nursing research is being conducted in many areas of marrow transplantation. Quality-of-life and survivor issues have been identified as priorities by many nurses working in this field. Nurses will continue to play a pivotal role in caring for patients as marrow transplantation continues to evolve as a major form of cancer treatment. 34

Thank you Merci Gracie Kiitos Tack Gracias 35

Thank you Merci Gracie Kiito Tack Gracias